Pfizer Inc. reported strong earnings and guidance, leading to a rise in its stock price to $27.72 on Feb. 11. Unusual call option activity suggests bullish sentiment, with over 25,000 contracts traded for a $31.00 strike price expiring on Sept. 18, 2026. Investors may expect a 15% upside potential.

Despite a 2% revenue decline in 2025, Pfizer’s adjusted revenue rose 6% to $17.56 billion in Q4, beating analysts’ estimates by $729.44 million. Adjusted EPS of $0.66 exceeded expectations by $0.09. The company reaffirmed its revenue guidance and projected EPS between $2.80 and $3.00.

Analysts suggest that PFE stock may be undervalued, with target prices ranging from $29.00 to $34.79 per share. Investors are flocking to long-dated call options with a $31.00 exercise price, indicating a bullish outlook. However, caution is advised as the stock price needs to rise by 15% for potential profit.

Read more at Barchart: Pfizer Reports Strong Earnings Outlook